clinical practice guidelines

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Approved by the ESMO Guidelines Working Group: February 2002, last update December 2009. This publication supercedes the previously published version—Ann Oncol 2009; 20 (Suppl 4): iv68-iv70.

Conflict of interest: Dr D'Addario has reported no conflicts of interest; Dr Früh has reported that he is currently participating as an investigator on a phase III study sponsored by Novartis; Dr Reck has reported that he is a member of the advisory board of Lilly, Merck, Hoffmann-La Roche and Astra Zeneca and that he has received honoraria from Lilly, Merck, Hoffmann-La Roche and Astra Zeneca; Dr Baumann, Dr Klepetko and Dr Felip have reported no conflicts of interest.